<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="543aa8e5-219e-41d8-8ffa-9ae1446d3391"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>INDOMETHACIN EXTENDED RELEASE CAPSULES 75MG USP</title>
   <effectiveTime value="20100416"/>
   <setId root="6569dfd1-0164-4241-b508-ccd540d1e858"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="051457844" root="1.3.6.1.4.1.519.1"/>
            <name>Apotheca, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="051457844" root="1.3.6.1.4.1.519.1"/>
                        <name>Apotheca, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="relabel"/>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="repack"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="f2eec97e-7444-4076-9705-0a1c55df472d"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL listing data elements section"/>
               <effectiveTime value="20100416"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="12634-160" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>INDOMETHACIN ER<suffix/>
                        </name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>INDOMETHACIN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="10702-016" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="75" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="XXE1CET956" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>INDOMETHACIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="XXE1CET956" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INDOMETHACIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="35SW5USQ3G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C YELLOW NO. 10</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-91" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="14" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-54" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-55" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-57" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="25" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-25" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-59" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="7" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-97" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-00" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="14" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-84" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-85" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-80" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="25" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-79" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-71" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-160-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100304"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA079175" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText>YELLOW OPAQUE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText>CAPSULE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">K;16</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="15" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="12634-838" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>INDOMETHACIN ER<suffix/>
                        </name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>INDOMETHACIN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="0185-0720" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="75" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="XXE1CET956" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>INDOMETHACIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="XXE1CET956" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>INDOMETHACIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="35SW5USQ3G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C YELLOW NO. 10</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3P3ONR6O1S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C GREEN NO. 3</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="BPV390UAP0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURETH SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-91" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="6" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-66" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="7" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-67" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-61" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="14" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-54" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-55" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-57" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-59" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-95" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="7" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-97" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-00" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="14" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-84" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-85" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-80" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="25" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-79" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-71" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-50" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1">
                                 <translation code="C48480" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="12634-838-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20060502"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA074464" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="green" xsi:type="CE">
                              <originalText>green clear</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText>capsule</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">E;720</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="17" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="ed1f1de2-7362-42f0-ad29-44bc8446f8ae"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>BOXED WARNING</title>
               <text>Cardiovascular Risk<list listType="unordered" ID="i0d7eb5dd-f1d7-48da-8c05-d11b9e280726">
                     <item>NSAIDs may cause an increased risk of serious cardiovascular thrombotic 
events, myocardial infarction, and stroke, which can be fatal. This risk may 
increase with duration of use. Patients with cardiovascular disease or risk 
factors for cardiovascular disease may be at greater risk <content styleCode="bold">(see WARNINGS)</content>
                        <content styleCode="bold">.</content>
                     </item>
                     <item>Indomethacin is contraindicated for the treatment of perioperative pain in 
the setting of coronary artery bypass graft (CABG) surgery <content styleCode="bold">(see WARNING)</content>. 
</item>
                  </list>
                  <linkHtml href=""/>Gastrointestinal Risk<list listType="unordered" ID="i79dbc2d0-2830-4f2d-88ac-a3cdbe347570">
                     <item>NSAIDs cause an increased risk of serious gastrointestinal adverse events 
including bleeding, ulceration, and perforation of the stomach or intestines, 
which can be fatal. These events can occur at any time during use and without 
warning symptoms. Elderly patients are at greater risk for serious 
gastrointestinal events <content styleCode="bold">(see WARNINGS).</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20100305"/>
            </section>
         </component>
         <component>
            <section>
               <id root="3f603e13-9859-40bc-96f8-d41043dcffaa"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Indomethacin Capsules, USP for oral administration are provided 
in one dosage strengths which contain 75 mg of indomethacin. Indomethacin is a 
non-steroidal anti-inflammatory indole derivative designated chemically as 
1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1<content styleCode="italics">H</content>-indole-3-acetic acid. </paragraph>
                  <paragraph>The structural formula is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <br/>C<sub>19</sub>H<sub>16</sub>ClNO<sub>4</sub>       M.W. 357.79</paragraph>
                  <paragraph>Manufacture KVK-Tech. Inc. Each extended release capsule contains 75 mg of Indomethacin. In addition each capsule contains the following inactive ingredients:<br/>corn starch, D and C yellow #10, gelatin, mannitol, povidone, sucrose, talc, and titanium dioxide.<br/>
                  </paragraph>
                  <paragraph>Manufacture Sandoz, Inc.Each extended-release capsule, for oral administration contains 75 mg of 
indomethacin. In addition, each capsule contains the following inactive 
ingredients: D and C yellow No. 10, D and C yellow No. 10 aluminum lake, 
FD and C blue No. 1 aluminum lake, FD and C blue No. 2 aluminum lake, FD and C 
red No. 40 aluminum lake, FD and C green No. 3, ethylcellulose, gelatin, lactose 
monohydrate, povidone, silicon dioxide, sodium lauryl sulfate, corn starch, 
sucrose, talc and titanium dioxide.<br/>This product meets USP Drug Release Test 2 Specifications.</paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20100305"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM1">
                     <text>image of structural formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="indo-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="11033e72-2574-4e66-906b-b647658920da"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) 
that exhibits antipyretic and analgesic properties. Its mode of action, like 
that of other anti-inflammatory drugs, is not known. However, its therapeutic 
action is not due to pituitary-adrenal stimulation.</paragraph>
                  <paragraph>Indomethacin is a potent inhibitor of prostaglandin synthesis <content styleCode="italics">in vitro.</content> Concentrations are reached during therapy which 
have been demonstrated to have an effect <content styleCode="italics">in vivo</content> as 
well. Prostaglandins sensitize afferent nerves and potentiate the action of 
bradykinin in inducing pain in animal models. Moreover, prostaglandins are known 
to be among the mediators of inflammation. Since indomethacin is an inhibitor of 
prostaglandin synthesis, its mode of action may be due to a decrease of 
prostaglandins in peripheral tissues. </paragraph>
                  <paragraph>Indomethacin has been shown to be an effective anti-inflammatory agent, 
appropriate for long-term use in rheumatoid arthritis, ankylosing spondylitis, 
and osteoarthritis.</paragraph>
                  <paragraph>Indomethacin affords relief of symptoms; it does not alter the progressive 
course of the underlying disease.</paragraph>
                  <paragraph>Indomethacin suppresses inflammation in rheumatoid arthritis as demonstrated 
by relief of pain, and reduction of fever, swelling and tenderness. Improvement 
in patients treated with indomethacin for rheumatoid arthritis has been 
demonstrated by a reduction in joint swelling, average number of joints 
involved, and morning stiffness; by increased mobility as demonstrated by a 
decrease in walking time; and by improved functional capability as demonstrated 
by an increase in grip strength. Indomethacin may enable the reduction of 
steroid dosage in patients receiving steroids for the more severe forms of 
rheumatoid arthritis. In such instances the steroid dosage should be reduced 
slowly and the patients followed very closely for any possible adverse 
effects.</paragraph>
                  <paragraph>Indomethacin has been reported to diminish basal and CO<sub>2</sub> stimulated cerebral blood flow in healthy volunteers 
following acute oral and intravenous administration. In one study, after one 
week of treatment with orally administered indomethacin, this effect on basal 
cerebral blood flow had disappeared. The clinical significance of this effect 
has not been established. </paragraph>
                  <paragraph>Indomethacin capsules have been found effective in relieving the pain, 
reducing the fever, swelling, redness, and tenderness of acute gouty arthritis <content styleCode="bold">(see indications and usage).</content>
                  </paragraph>
                  <paragraph>Following single oral doses of indomethacin capsules 25 mg or 50 mg, 
indomethacin is readily absorbed, attaining peak plasma concentrations of about 
1 and 2 mcg/mL, respectively, at about 2 hours. Orally administered indomethacin 
capsules are virtually 100% bioavailable, with 90% of the dose absorbed within 4 
hours. A single 50 mg dose of indomethacin oral suspension was found to be 
bioequivalent to a 50 mg indomethacin capsule when each was administered with 
food.</paragraph>
                  <paragraph>Indomethacin is eliminated via renal excretion, metabolism, and biliary 
excretion. Indomethacin undergoes appreciable enterohepatic circulation. The 
mean half-life of indomethacin is estimated to be about 4.5 hours. With a 
typical therapeutic regimen of 25 mg or 50 mg t.i.d., the steady-state plasma 
concentrations of indomethacin are an average 1.4 times those following the 
first dose.</paragraph>
                  <paragraph>Indomethacin exists in the plasma as the parent drug and its desmethyl, 
desbenzoyl, and desmethyl-desbenzoyl metabolites, all in the unconjugated form. 
About 60% of an oral dosage is recovered in urine as drug and metabolites (26% 
as indomethacin and its glucuronide), and 33% is recovered in feces (1.5% as 
indomethacin).</paragraph>
                  <paragraph>About 99% of indomethacin is bound to protein in plasma over the expected 
range of therapeutic plasma concentrations. Indomethacin has been found to cross 
the blood-brain barrier and the placenta.</paragraph>
               </text>
               <effectiveTime value="20100305"/>
            </section>
         </component>
         <component>
            <section>
               <id root="1407bdbf-6649-4fe4-9159-725d99875c29"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Carefully consider the potential benefits and risks of 
indomethacin capsules and other treatment options before deciding to use 
indomethacin. Use the lowest effective dose for the shortest duration consistent 
with individual patient treatment goals <content styleCode="bold">(see WARNINGS)</content>
                  </paragraph>
                  <paragraph>Indomethacin has been found effective in active stages of the following:</paragraph>
                  <list listType="ordered" ID="idd1b940f-cce4-4776-8794-eac96a90e844">
                     <item>Moderate to severe rheumatoid arthritis including acute flares of chronic 
disease. 
</item>
                     <item>Moderate to severe ankylosing spondylitis. 
</item>
                     <item>Moderate to severe osteoarthritis. 
</item>
                     <item>Acute painful shoulder (bursitis and/or tendinitis). 
</item>
                     <item>Acute gouty arthritis.</item>
                  </list>
               </text>
               <effectiveTime value="20100305"/>
            </section>
         </component>
         <component>
            <section>
               <id root="8b866fb0-5896-46f0-b921-fcec34e28636"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Indomethacin is contraindicated in patients with known 
hypersensitivity to indomethacin or the excipients (see DESCRIPTION). 
</paragraph>
                  <paragraph>Indomethacin should not be given to patients who have experienced asthma, 
urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. 
Severe, rarely fatal, anaphylactic/anaphylactoid reactions to NSAIDs have been 
reported in such patients <content styleCode="bold">(see WARNINGS: </content>
                     <content styleCode="italics">
                        <content styleCode="bold">Anaphylactic/Anaphylactoid Reactions,</content>
                     </content> and <content styleCode="bold">PRECAUTIONS:</content>
                     <content styleCode="bold">
                        <content styleCode="bold"/>
                        <content styleCode="italics">General:preexisting Asthma).</content>
                     </content>
                     <content styleCode="italics"/>
                  </paragraph>
                  <paragraph>Indomethacin is contraindicated for the treatment of perioperative pain in 
the setting of coronary artery bypass graft (CABG) surgery <content styleCode="bold">(see WARNINGS).</content>
                  </paragraph>
               </text>
               <effectiveTime value="20100305"/>
            </section>
         </component>
         <component>
            <section>
               <id root="a89c105d-a49c-4788-ab6b-86fc6d816519"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <content styleCode="bold">Cardiovascular Effects</content>
                  <br/>
                  <content styleCode="bold">Cardiovascular Thrombotic Events</content>
                  <paragraph>Clinical trials of several COX-2 selective and nonselective 
NSAIDs of up to 3 years duration have shown an increased risk of serious 
cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which 
can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a 
similar risk. Patients with known CV disease or risk factors for CV disease may 
be at greater risk. To minimize the potential risk for an adverse CV event in 
patients treated with an NSAID, the lowest effective dose should be used for the 
shortest duration possible. Physicians and patients should remain alert for the 
development of such events, even in the absence of previous CV symptoms. 
Patients should be informed about the signs and/or symptoms of serious CV events 
and the steps to take if they occur.</paragraph>
                  <paragraph>There is no consistent evidence that concurrent use of aspirin mitigates the 
increased risk of serious CV thrombotic events associated with NSAID use. The 
concurrent use of aspirin and an NSAID does increase the risk of serious GI 
events <content styleCode="bold">(see WARNINGS: 
Gastrointestinal Effects).</content>
                  </paragraph>
                  <paragraph>Two large, controlled, clinical trials of a COX-2 selective NSAID for the 
treatment of pain in the first 10 to 14 days following CABG surgery found an 
increased incidence of myocardial infarction and stroke <content styleCode="bold">(see CONTRAINDICATIONS).</content>
                  </paragraph>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">Hypertension</content>
                  <paragraph>NSAIDs, including indomethacin, can lead to onset of new 
hypertension or worsening of preexisting hypertension, either of which may 
contribute to the increased incidence of CV events. Patients taking thiazides or 
loop diuretics may have impaired response to these therapies when taking NSAIDs. 
NSAIDs, including indomethacin, should be used with caution in patients with 
hypertension. Blood pressure (BP) should be monitored closely during the 
initiation of NSAID treatment and throughout the course of therapy.</paragraph>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">Congestive Heart Failure and Edema</content>
                  <paragraph>Fluid retention and edema have been observed in some patients 
taking NSAIDs. Indomethacin should be used with caution in patients with fluid 
retention or heart failure.</paragraph>
                  <paragraph>In a study of patients with severe heart failure and hyponatremia, 
indomethacin was associated with significant deterioration of circulatory 
hemodynamics, presumably due to inhibition of prostaglandin dependent 
compensatory mechanisms.</paragraph>
               </text>
               <effectiveTime value="20100305"/>
               <component>
                  <section>
                     <id root="ba7ea0d6-60bd-4efa-bc26-89fbd3a80d28"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title>Gastrointestinal Effects</title>
                     <text>Risk of Ulceration, Bleeding, and Perforation<paragraph>NSAIDs, including indomethacin, can cause serious 
gastrointestinal (GI) adverse events including inflammation, bleeding, 
ulceration, and perforation of the esophagus, stomach, small intestine, or large 
intestine, which can be fatal. These serious adverse events can occur at any 
time, with or without warning symptoms, in patients treated with NSAIDs. Only 
one in five patients, who develop a serious upper GI adverse event on NSAID 
therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused 
by NSAIDs occur in approximately 1% of patients treated for 3 to 6 months, and 
in about 2 to 4% of patients treated for one year. These trends continue with 
longer duration of use, increasing the likelihood of developing a serious GI 
event at some time during the course of therapy. However, even short-term 
therapy is not without risk.</paragraph>
                        <paragraph>Rarely, in patients taking indomethacin, intestinal ulceration has been 
associated with stenosis and obstruction. Gastrointestinal bleeding without 
obvious ulcer formation and perforation of preexisting sigmoid lesions 
(diverticulum, carcinoma, etc.) have occurred. Increased abdominal pain in 
ulcerative colitis patients or the development of ulcerative colitis and 
regional ileitis have been reported to occur rarely.</paragraph>
                        <paragraph>NSAIDs should be prescribed with extreme caution in those with a prior 
history of ulcer disease or gastrointestinal bleeding. Patients with a <content styleCode="italics">prior history of peptic ulcer disease and/or gastrointestinal 
bleeding</content> who use NSAIDs have a greater than 10-fold increased risk for 
developing a GI bleed compared to patients with neither of these risk factors. 
Other factors that increase the risk for GI bleeding in patients treated with 
NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer 
duration of NSAID therapy, smoking, use of alcohol, older age, and poor general 
health status. Most spontaneous reports of fatal GI events are in elderly or 
debilitated patients and therefore, special care should be taken in treating 
this population. </paragraph>
                        <paragraph>To minimize the potential risk for an adverse GI event in patients treated 
with an NSAID, the lowest effective dose should be used for the shortest 
possible duration. Patients and physicians should remain alert for signs and 
symptoms of GI ulceration and bleeding during NSAID therapy and promptly 
initiate additional evaluation and treatment if a serious GI adverse event is 
suspected. This should include discontinuation of the NSAID until a serious GI 
adverse event is ruled out. For high risk patients, alternate therapies that do 
not involve NSAIDs should be considered.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="cc093c3b-f282-43bc-9efa-3ced4e385978"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title>Renal Effects</title>
                     <text>
                        <paragraph>Long-term administration of NSAIDs has resulted in renal 
papillary necrosis and other renal injury. Renal toxicity has also been seen in 
patients in whom renal prostaglandins have a compensatory role in the 
maintenance of renal perfusion. In these patients, administration of a 
non-steroidal anti-inflammatory drug may cause a dose dependent reduction in 
prostaglandin formation and, secondarily, in renal blood flow, which may 
precipitate over renal decompensation. Patients at greatest risk of this 
reaction are those with impaired renal function, heart failure, liver 
dysfunction, those taking diuretics and ACE inhibitors, patients with volume 
depletion, and the elderly. Discontinuation of NSAID therapy is usually followed 
by recovery to the pretreatment state.</paragraph>
                        <paragraph>Increases in serum potassium concentration, including hyperkalemia, have been 
reported with use of indomethacin, even in some patients without renal 
impairment. In patients with normal renal function, these effects have been 
attributed to a hyporeninemic-hypoaldosteronism state <content styleCode="bold">(see PRECAUTIONS: 
Drug Interactions).</content>
                        </paragraph>
                        <linkHtml href=""/>Advanced Renal Disease<paragraph>No information is available from controlled clinical studies 
regarding the use of indomethacin in patients with advanced renal disease. 
Therefore, treatment with indomethacin is not recommended in these patients with 
advanced renal disease. If indomethacin therapy must be initiated, close 
monitoring of the patient's renal function is advisable.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="14e5dded-ab4f-475c-9e84-d458f0b81e81"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title>Advanced Renal Disease</title>
                     <text>No information is available from controlled clinical studies regarding the use 
of indomethacin in patients with advanced renal disease. Therefore, treatment 
with indomethacin is not recommended in these patients with advanced renal 
disease. If indomethacin therapy must be initiated, close monitoring of the 
patient's renal function is advisable.</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5cc394f2-b969-41ac-9447-dd0d2d196ae5"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title>Anaphylactic/Anaphylactoid Reactions</title>
                     <text>As with other NSAIDs, anaphylactic/anaphylactoid reactions may occur in patients 
without known prior exposure to indomethacin. Indomethacin should not be given 
to patients with the aspirin triad. This symptom complex typically occurs in 
asthmatic patients who experience rhinitis with or without nasal polyps, or who 
exhibit severe, potentially fatal bronchospasm after taking aspirin or other 
NSAIDs <content styleCode="bold">(see CONTRAINDICATIONS 
and PRECAUTIONS: 
General: Preexisting Asthma).</content> Emergency help should be sought in cases where 
an anaphylactic/anaphylactoid reaction occurs. </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ed1a434b-038c-4218-a939-3e5c6d1de9fc"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title>Skin Reactions</title>
                     <text>NSAIDs, including indomethacin, can cause serious skin adverse events such as 
exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal 
necrolysis (TEN), which can be fatal. These serious events may occur without 
warning. Patients should be informed about the signs and symptoms of serious 
skin manifestations and use of the drug should be discontinued at the first 
appearance of skin rash or any other sign of hypersensitivity.</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f494b22d-27b2-460d-94e2-d51a5db9f7ec"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title>Pregnancy</title>
                     <text>In late pregnancy, as with other NSAIDs, indomethacin should be avoided because 
it may cause premature closure of the ductus arteriosus.</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="59718c1d-9924-4447-9afa-07bfbf846cbf"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title>Ocular Effects</title>
                     <text>Corneal deposits and retinal disturbances, including those of the macula, have 
been observed in some patients who had received prolonged therapy with 
indomethacin. The prescribing physician should be alert to the possible 
association between the changes noted and indomethacin. It is advisable to 
discontinue therapy if such changes are observed. Blurred vision may be a 
significant symptom and warrants a thorough ophthalmological examination. Since 
these changes may be asymptomatic, ophthalmologic examination at periodic 
intervals is desirable in patients where therapy is prolonged.</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d6cd80ac-6a66-4768-8143-032d6b14b33c"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title>Central Nervous System Effects</title>
                     <text>
                        <paragraph>Indomethacin may aggravate depression or other psychiatric 
disturbances, epilepsy, and parkinsonism, and should be used with considerable 
caution in patients with these conditions. If severe CNS adverse reactions 
develop, indomethacin should be discontinued.</paragraph>
                        <paragraph>Indomethacin may cause drowsiness; therefore, patients should be cautioned 
about engaging in activities requiring mental alertness and motor coordination, 
such as driving a car. Indomethacin may also cause headache. Headache which 
persists despite dosage reduction requires cessation of therapy with 
indomethacin.</paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="f590d9c7-d641-4d28-b8b0-bdd02fc0495f"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <content styleCode="bold">GENERAL</content>
                  <paragraph>Indomethacin cannot be expected to substitute for corticosteroids 
or to treat corticosteroid insufficiency. Abrupt discontinuation of 
corticosteroids may lead to disease exacerbation. Patients on prolonged 
corticosteroid therapy should have their therapy tapered slowly if a decision is 
made to discontinue corticosteroids.</paragraph>
                  <paragraph>The pharmacological activity of indomethacin in reducing fever and 
inflammation may diminish the utility of these diagnostic signs in detecting 
complications of presumed noninfectious, painful conditions.</paragraph>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">Hepatic Effects</content>
                  <paragraph>Borderline elevations of one or more liver tests may occur in up 
to 15% of patients taking NSAIDs, including indomethacin. These laboratory 
abnormalities may progress, may remain unchanged, or may be transient with 
continuing therapy. Notable elevations of ALT or AST (approximately three or 
more times the upper limit of normal) have been reported in approximately 1% of 
patients in clinical trials with NSAIDs. In addition, rare cases of severe 
hepatic reactions, including jaundice and fatal fulminant hepatitis, liver 
necrosis and hepatic failure, some of them with fatal outcomes have been 
reported.</paragraph>
                  <paragraph>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom 
an abnormal liver test values has occured, should be evaluated for evidence of 
the development of a more severe hepatic reaction while on therapy with 
indomethacin. If clinical signs and symptoms consistent with liver disease 
develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), 
indomethacin should be discontinued.</paragraph>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">Hematological Effects</content>
                  <paragraph>Anemia is sometimes seen in patients receiving NSAIDs, including 
indomethacin. This may be due to fluid retention, occult or gross GI blood loss, 
or an incompletely described effect upon erythropoiesis. Patients on long-term 
treatment with NSAIDs, including indomethacin, should have their hemoglobin or 
hematocrit checked if they exhibit any signs or symptoms of anemia.</paragraph>
                  <paragraph>NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding 
time in some patients. Unlike aspirin, their effect on platelet function is 
quantitatively less, of shorter duration, and reversible. Patients receiving 
indomethacin who may be adversely affected by alterations in platelet function, 
such as those with coagulation disorders or patients receiving anticoagulants, 
should be carefully monitored.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">Preexisting Asthma</content>
                  <paragraph>Patients with asthma may have aspirin-sensitive asthma. The use 
of aspirin in patients with aspirin-sensitive asthma has been associated with 
severe bronchospasm which can be fatal. Since cross-reactivity, including 
bronchospasm, between aspirin and other non-steroidal anti-inflammatory drugs 
has been reported in such aspirin-sensitive patients, indomethacin should not be 
administered to patients with this form of aspirin sensitivity and should be 
used with caution in patients with preexisting asthma.</paragraph>
               </text>
               <effectiveTime value="20100305"/>
               <component>
                  <section>
                     <id root="583dce5d-d2b2-4e71-b2f2-76395a222221"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>INFORMATION FOR PATIENTS</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Patients should be informed of the following 
information before initiating therapy with an NSAID and periodically during the 
course of ongoing therapy. Patients should also be encouraged to read the NSAID 
Medication Guide that accompanies each prescription dispensed</content>.</paragraph>
                        <list listType="ordered" ID="i9668070b-b280-4685-815b-8da2dca3f5c3">
                           <item>Indomethacin, like other NSAIDs, may cause serious CV side effects, such as 
MI or stroke, which may result in hospitalization and even death. Although 
serious CV events can occur without warning symptoms, patients should be alert 
for the signs and symptoms of chest pain, shortness of breath, weakness, 
slurring of speech, and should ask for medical advice when observing any 
indicative sign or symptoms. Patients should be apprised of the importance of 
this follow-up <content styleCode="bold">(see WARNINGS: 
Cardiovascular Effects).</content>
                           </item>
                           <item>Indomethacin, like other NSAIDs, can cause GI discomfort and, rarely, 
serious GI side effects, such as ulcers and bleeding, which may result in 
hospitalization and even death. Although serious GI tract ulcerations and 
bleeding can occur without warning symptoms, patients should be alert for the 
signs and symptoms of ulcerations and bleeding, and should ask for medical 
advice when observing any indicative signs or symptoms including epigastric 
pain, dyspepsia, melena, and hematemesis. Patients should be apprised of the 
importance of this follow-up (see <content styleCode="bold">WARNINGS: 
Gastrointestinal Effects: Risk of Ulceration, Bleeding, and Perforation).</content>
                           </item>
                           <item>Indomethacin, like other NSAIDs, can cause serious skin side effects such as 
exfoliative dermatitis, SJS, and TEN, which may result in hospitalizations and 
even death. Although serious skin reactions may occur without warning, patients 
should be alert for the signs and symptoms of skin rash and blisters, fever, or 
other signs of hypersensitivity such as itching, and should ask for medical 
advice when observing any indicative signs or symptoms. Patients should be 
advised to stop the drug immediately if they develop any type of rash and 
contact their physicians as soon as possible. 
</item>
                           <item>Patients should promptly report signs or symptoms of unexplained weight gain 
or edema to their physicians. 
</item>
                           <item>Patients should be informed of the warning signs and symptoms of 
hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper 
quadrant tenderness and "flu-like" symptoms). If these occur, patients should be 
instructed to stop therapy and seek immediate medical therapy. 
</item>
                           <item>Patients should be informed of the signs of an anaphylactic/anaphylactoid 
reaction (e.g. difficulty breathing, swelling of the face or throat). If these 
occur, patients should be instructed to seek immediate emergency help<content styleCode="bold"> (see</content>
                              <content styleCode="bold">
                                 <content styleCode="bold"/>WARNINGS).</content>
                              <content styleCode="bold"/>
                           </item>
                           <item>In late pregnancy, as with other NSAIDs, indomethacin should be avoided 
because it may cause premature closure of the ductus arteriosus.</item>
                        </list>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="eb6bc41e-2890-4abd-abcf-315f03348417"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>LABORATORY TESTS</title>
                     <text>Because serious GI tract ulcerations and bleeding can occur without warning 
symptoms, physicians should monitor for signs or symptoms of GI bleeding. 
Patients on long-term treatment with NSAIDs should have their CBC and a 
chemistry profile checked periodically. If clinical signs and symptoms 
consistent with liver or renal disease develop, systemic manifestations occur 
(e.g., eosinophilia, rash, etc.) or if abnormal liver tests persist or worsen, 
indomethacin should be discontinued</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a2112ce7-7fd4-46f5-a8a2-727a032df915"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>DRUG INTERACTIONS</title>
                     <text>
                        <content styleCode="bold">ACE Inhibitors and Angiotensin II Antagonists</content>
                        <paragraph>Reports suggest that NSAIDs may diminish the antihypertensive 
effect of ACE inhibitors and angiotensin II antagonists. Indomethacin can reduce 
the antihypertensive effects of captopril and losartan. These interactions 
should be given consideration in patients taking NSAIDs concomitantly with ACE 
inhibitors or angiotensin II antagonists. In some patients with compromised 
renal function, the coadministration of an NSAID and an ACE inhibitor or an 
angiotensin II antagonist may result in further deterioration of renal function, 
including possible acute renal failure, which is usually reversible.</paragraph>
                        <linkHtml href=""/>
                        <content styleCode="bold">Aspirin</content>
                        <paragraph>When indomethacin is administered with aspirin, its protein 
binding is reduced, although the clearance of free indomethacin is not altered. 
The clinical significance of this interaction is not known.</paragraph>
                        <paragraph>The use of indomethacin in conjunction with aspirin or other salicylates is 
not recommended. Controlled clinical studies have shown that the combined use of 
indomethacin and aspirin does not produce any greater therapeutic effect than 
the use of indomethacin alone. In a clinical study of the combined use of 
indomethacin and aspirin, the incidence of gastrointestinal side effects was 
significantly increased with combined therapy.</paragraph>
                        <paragraph>In a study in normal volunteers, it was found that chronic concurrent 
administration of 3.6 g of aspirin per day decreases indomethacin blood levels 
approximately 20%.</paragraph>
                        <linkHtml href=""/>
                        <content styleCode="bold">Beta-Adrenoceptor Blocking Agents</content>
                        <paragraph>Blunting of the antihypertensive effect of beta-adrenoceptor 
blocking agents by non-steroidal anti-inflammatory drugs including indomethacin 
has been reported. Therefore, when using these blocking agents to treat 
hypertension, patients should be observed carefully in order to confirm that the 
desired therapeutic effect has been obtained.</paragraph>
                        <linkHtml href=""/>
                        <content styleCode="bold">Cyclosporin</content>
                        <paragraph>Administration of non-steroidal anti-inflammatory drugs 
concomitantly with cyclosporine has been associated with an increase in 
cyclosporine-induced toxicity, possibly due to decreased synthesis of renal 
prostacyclin. NSAIDs should be used with caution in patients taking 
cyclosporine, and renal function should be carefully monitored.</paragraph>
                        <linkHtml href=""/>
                        <content styleCode="bold">Diflunisal</content>
                        <paragraph>In normal volunteers receiving indomethacin, the administration 
of diflunisal decreased the renal clearance and significantly increased the 
plasma levels of indomethacin. In some patients, combined use of indomethacin 
and diflunisal has been associated with fatal gastrointestinal hemorrhage. 
Therefore, diflunisal and indomethacin should not be used concomitantly.</paragraph>
                        <linkHtml href=""/>
                        <content styleCode="bold">Digoxin</content>
                        <paragraph>Indomethacin given concomitantly with digoxin has been reported 
to increase the serum concentration and prolong the half-life of digoxin. 
Therefore, when indomethacin and digoxin are used concomitantly, serum digoxin 
levels should be closely monitored.</paragraph>
                        <linkHtml href=""/>
                        <content styleCode="bold">Diuretics</content>
                        <paragraph>In some patients, the administration of indomethacin can reduce 
the diuretic, natriuretic, and antihypertensive effects of loop, 
potassium-sparing, and thiazide diuretics. This response has been attributed to 
inhibition of renal prostaglandin synthesis.</paragraph>
                        <paragraph>Indomethacin reduces basal plasma renin activity (PRA), as well as those 
elevations of PRA induced by furosemide administration, or salt or volume 
depletion. These facts should be considered when evaluating plasma renin 
activity in hypertensive patients.</paragraph>
                        <paragraph>It has been reported that the addition of triamterene to a maintenance 
schedule of indomethacin resulted in reversible acute renal failure in two of 
four healthy volunteers. Indomethacin and triamterene should not be administered 
together.</paragraph>
                        <paragraph>Indomethacin and potassium-sparing diuretics each may be associated with 
increased serum potassium levels. The potential effects of indomethacin and 
potassium-sparing diuretics on potassium kinetics and renal function should be 
considered when these agents are administered concurrently. Most of the above 
effects concerning diuretics have been attributed, at least in part, to 
mechanisms involving inhibition of prostaglandin synthesis by indomethacin.</paragraph>
                        <paragraph>During concomitant therapy with NSAIDs, the patient should be observed 
closely for signs of renal failure <content styleCode="bold">(see WARNINGS: 
Renal Effects)</content>, as well as to assure diuretic efficacy.</paragraph>
                        <linkHtml href=""/>
                        <content styleCode="bold">Lithium</content>
                        <paragraph>Indomethacin capsules 50 mg t.i.d. produced a clinically relevant 
elevation of plasma lithium and reduction in renal lithium clearance in 
psychiatric patients and normal subjects with steady-state plasma lithium 
concentrations. This effect has been attributed to inhibition of prostaglandin 
synthesis. As a consequence, when NSAIDs and lithium are given concomitantly, 
the patient should be carefully observed for signs of lithium toxicity. (Read 
circulars for lithium preparations before use of such concomitant therapy.) In 
addition, the frequency of monitoring serum lithium concentration should be 
increased at the outset of such combination drug treatment.</paragraph>
                        <linkHtml href=""/>
                        <content styleCode="bold">Methotrexate</content>
                        <paragraph>NSAIDs have been reported to competitively inhibit methotrexate 
accumulation in rabbit kidney slices. This may indicate that they could enhance 
the toxicity of methotrexate. Caution should be used when NSAIDs are 
administered concomitantly with methotrexate.</paragraph>
                        <linkHtml href=""/>
                        <content styleCode="bold">NSAIDs</content>
                        <paragraph>The concomitant use of indomethacin with other NSAIDs is not 
recommended due to the increased possibility of gastrointestinal toxicity, with 
little or no increase in efficacy.</paragraph>
                        <linkHtml href=""/>
                        <content styleCode="bold">Oral anticoagulants</content>
                        <paragraph>Clinical studies have shown that indomethacin does not influence 
the hypoprothrombinemia produced by anticoagulants. However, when any additional 
drug, including indomethacin, is added to the treatment of patients on 
anticoagulant therapy, the patients should be observed for alterations of the 
prothrombin time. In post-marketing experience, bleeding has been reported in 
patients on concomitant treatment with anticoagulants and indomethacin. Caution 
should be exercised when indomethacin and anticoagulants are administered 
concomitantly. The effects of warfarin and NSAIDs on GI bleeding are 
synergistic, such that users of both drugs together have a risk of serious GI 
bleeding higher than users of either drug alone.</paragraph>
                        <linkHtml href=""/>
                        <content styleCode="bold">Probenecid</content>
                        <paragraph>When indomethacin is given to patients receiving probenecid, the 
plasma levels of indomethacin are likely to be increased. Therefore, a lower 
total daily dosage of indomethacin may produce a satisfactory therapeutic 
effect. When increases in the dose of indomethacin are made, they should be made 
carefully and in small increments.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b6718612-6281-424f-9516-1132add2ccaf"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>DRUG/LABORATORY TEST INTERACTIONS</title>
                     <text>False-negative results in the dexamethasone suppression test (DST) in patients 
being treated with indomethacin have been reported. Thus, results of the DST 
should be interpreted with caution in these patients</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="77630ba2-56a1-47a2-b387-6fbf57a7911a"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY</title>
                     <text>
                        <paragraph>In an 81-week chronic oral toxicity study in the rat at doses up 
to 1 mg/kg/day, indomethacin had no tumorigenic effect.</paragraph>
                        <paragraph>Indomethacin produced no neoplastic or hyperplastic changes related to 
treatment in carcinogenic studies in the rat (dosing period 73 to 110 weeks) and 
the mouse (dosing period 62 to 88 weeks) at doses up to 1.5 mg/kg/day.</paragraph>
                        <paragraph>Indomethacin did not have any mutagenic effect in <content styleCode="italics">in 
vitro</content> bacterial tests (Ames test and <content styleCode="italics">E. coli</content> 
with or without metabolic activation) and a series of <content styleCode="italics">in 
vivo</content> tests including the host-mediated assay, sex-linked recessive 
lethals in <content styleCode="italics">Drosophila</content>, and the micronucleus test in 
mice.</paragraph>
                        <paragraph>Indomethacin at dosage levels up to 0.5 mg/kg/day had no effect on fertility 
in mice in a two generation reproduction study or a two litter reproduction 
study in rats.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="63245c48-21d7-42b9-88b9-cea247a018a4"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>PREGNANCY</title>
                     <text>
                        <content styleCode="bold">Teratogenic Effects. Pregnancy Category C</content>
                        <paragraph>Teratogenic studies were conducted in mice and rats at dosages of 
0.5, 1.0, 2.0, and 4.0 mg/kg/day. Except for retarded fetal ossification at 4 
mg/kg/day considered secondary to the decreased average fetal weights, no 
increase in fetal malformations was observed as compared with control groups. 
Other studies in mice reported in the literature using higher doses (5 to 15 
mg/kg/day) have described maternal toxicity and death, increased fetal 
resorptions, and fetal malformations. Comparable studies in rodents using high 
doses of aspirin have shown similar maternal and fetal effects. However, animal 
reproduction studies are not always predictive of human response. There are no 
adequate and well controlled studies in pregnant women.</paragraph>
                        <paragraph>Indomethacin should be used during pregnancy only if the potential benefit 
justifies the potential risk to the fetus.</paragraph>
                        <linkHtml href=""/>
                        <content styleCode="bold">Nonteratogenic Effects</content>
                        <paragraph>Because of the known effects of non-steroidal anti-inflammatory 
drugs on the fetal cardiovascular system (closure of ductus arteriosus), use 
during pregnancy (particularly late pregnancy) should be avoided.</paragraph>
                        <paragraph>The known effects of indomethacin and other drugs of this class on the human 
fetus during the third trimester of pregnancy include: constriction of the 
ductus arteriosus prenatally, tricuspid incompetence, and pulmonary 
hypertension; nonclosure of the ductus arteriosus postnatally which may be 
resistant to medical management; myocardial degenerative changes, platelet 
dysfunction with resultant bleeding, intracranial bleeding, renal dysfunction or 
failure, renal injury/dysgenesis which may result in prolonged or permanent 
renal failure, oligohydramnios, gastrointestinal bleeding or perforation, and 
increased risk of necrotizing enterocolitis.</paragraph>
                        <paragraph>In rats and mice, 4.0 mg/kg/day given during the last 3 days of gestation 
caused a decrease in maternal weight gain and some maternal and fetal deaths. An 
increased incidence of neuronal necrosis in the diencephalon in the live born 
fetuses was observed. At 2.0 mg/kg/day, no increase in neuronal necrosis was 
observed as compared to the control groups. Administration of 0.5 or 4.0 
mg/kg/day during the first 3 days of life did not cause an increase in neuronal 
necrosis at either dose level.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="737c4d79-9241-4291-89b1-448aa8899ec5"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>LABOR AND DELIVERY</title>
                     <text>In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin 
synthesis, an increased incidence of dystocia, delayed parturition, and 
decreased pup survival occurred. The effects of indomethacin on labor and 
delivery in pregnant women are unknown.</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3d2d6027-ee93-4ce4-9212-7d61deaec3a9"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>NURSING MOTHERS</title>
                     <text>Indomethacin is excreted in the milk of lactating mothers. Indomethacin is not 
recommended for use in nursing mothers.</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="93adde46-4b9f-4fa0-a5a7-a008877209d2"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>PEDIATRIC USE</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients 14 years of age 
and younger have not been established.</paragraph>
                        <paragraph>Indomethacin should not be prescribed for pediatric patients 14 years of age 
and younger unless toxicity or lack of efficacy associated with other drugs 
warrants the risk.</paragraph>
                        <paragraph>In experience with more than 900 pediatric patients reported in the 
literature or to the manufacturer who were treated with Capsules indomethacin, 
side effects in pediatric patients were comparable to those reported in adults. 
Experience in pediatric patients has been confined to the use of Capsules 
indomethacin.</paragraph>
                        <paragraph>If a decision is made to use indomethacin for pediatric patients 2 years of 
age or older, such patients should be monitored closely and periodic assessment 
of liver function is recommended. There have been cases of hepatotoxicity 
reported in pediatric patients with juvenile rheumatoid arthritis, including 
fatalities. If indomethacin treatment is instituted, a suggested starting dose 
is 1 to 2 mg/kg/day given in divided doses. Maximum daily dosage should not 
exceed 3 mg/kg/day or 150 to 200 mg/day, whichever is less. Limited data are 
available to support the use of a maximum daily dosage of 4mg/kg/day or 150 to 
200 mg/day, whichever is less. As symptoms subside, the total daily dosage 
should be reduced to the lowest level required to control symptoms, or the drug 
should be discontinued.</paragraph>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2107484a-7894-428c-900c-0ed3fec60223"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>GERIATRIC USE</title>
                     <text>
                        <paragraph>As with any NSAID, caution should be exercised in treating the 
elderly (65 years and older) since advancing age appears to increase the 
possibility of adverse reactions <content styleCode="bold">(see WARNINGS,</content>
                           <content styleCode="bold">Gastrointestinal Effects: Risk of Ulceration, Bleeding, and Perforation and DOSAGE 
AND ADMINISTRATION)</content>. Elderly patients seem to tolerate ulceration or 
bleeding less well than other individuals and many spontaneous reports of fatal 
GI events are in this population <content styleCode="bold">(see WARNINGS: 
Gastrointestinal Effects: Risk of Ulceration, Bleeding, and 
Perforation).</content>
                        </paragraph>
                        <paragraph>Indomethacin may cause confusion or, rarely, psychosis <content styleCode="bold">(see ADVERSE 
REACTIONS);</content> physicians should remain alert to the possibility of such 
adverse effects in the elderly.</paragraph>
                        <paragraph>This drug is known to be substantially excreted by the kidney and the risk of 
toxic reactions to this drug may be greater in patients with impaired renal 
function. Because elderly patients are more likely to have decreased renal 
function, care should be taken in dose selection and it may be useful to monitor 
renal function <content styleCode="bold">(see WARNINGS: 
Renal Effects).</content>
                        </paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="17786532-7f23-4b02-a61f-97fc3183b4fd"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>The adverse reactions for indomethacin capsules listed in the following table 
have been arranged into two groups: (1) incidence greater than 1%; and (2) 
incidence less than 1%. The incidence for group (1) was obtained from 33 
double-blind controlled clinical trials reported in the literature (1,092 
patients). The incidence for group (2) was based on reports in clinical trials, 
in the literature, and on voluntary reports since marketing. The probability of 
a causal relationship exists between indomethacin and these adverse reactions, 
some of which have been reported only rarely.<br/>
                  <content styleCode="bold">iNCIDENCE GREATER THAN 1%<br/>
                  </content>
                  <content styleCode="bold">GASTROINTESTINAL</content>
                  <br/>nausea with or without vomiting<br/>dyspepsia (including indigestion, heartburn and epigastric pain)<br/>diarrhea<br/>abdominal distress or pain<br/>constipation<br/>
                  <content styleCode="bold">CENTRAL NEVOUS SYSTEM<br/>
                  </content>headache<br/>dizziness<br/>vertigo<br/>somnolence<br/>depression and fatigue (including malaise and listlessness)<br/>
                  <content styleCode="bold">SPECIAL SENSES<br/>
                  </content>tinnitus<br/>
                  <content styleCode="bold">INCIDENCE LESS THAN 1%<br/>GASTROINTESTINAL<br/>
                  </content>anorexia<br/>bloating (includes distention)<br/>flatulence<br/>peptic 
ulcer<br/>gastroenteritis<br/>rectal bleeding<br/>proctitis<br/>single or multiple 
ulcerations, including perforation and hemorrhage of the esophagus, stomach, 
duodenum or small and large intestines<br/>intestinal ulceration associated with 
stenosis and obstruction<br/>gastrointestinal bleeding without obvious ulcer 
formation and perforation of preexisting sigmoid lesions (diverticulum, 
carcinoma, etc.) development of ulcerative colitis and regional 
ileitis<br/>ulcerative stomatitis<br/>toxic hepatitis and jaundice (some fatal 
cases have been reported)<br/>intestinal strictures (diaphragms)<content styleCode="bold">
                     <br/>CENTRAL NERVOUS SYSTEM<br/>
                  </content>anxiety (includes nervousness)<br/>muscle weakness<br/>involuntary muscle 
movements<br/>insomnia<br/>muzziness<br/>psychic disturbances including psychotic 
episodes<br/>mental 
confusion<br/>drowsiness<br/>light-headedness<br/>syncope<br/>paresthesia<br/>aggravation 
of epilepsy and parkinsonism<br/>depersonalization<br/>coma<br/>peripheral 
neuropathy<br/>convulsions<br/>dysarthria<br/>
                  <content styleCode="bold">SPECIAL SENSES<br/>
                  </content>ocular-corneal deposits and retinal disturbances, including those of the macula, have been reported in some<br/>patients on prolonged therapy with indomethacin.<br/>blurred vision<br/>diplopia<br/>hearing disturbances, deafness<br/>
                  <content styleCode="bold">CARDIOVASCULAR<br/>
                  </content>congestive heart failure<br/>hypertension<br/>hypotension<br/>tachycardia<br/>chest pain<br/>arrhythmia palpitations<br/>
                  <content styleCode="bold">
                     <br/>
                  </content>
                  <br/>
                  <content styleCode="bold">
                     <br/>
                     <content styleCode="bold">
                        <br/>
                        <br/>
                     </content>
                     <br/>
                     <br/>
                  </content>
               </text>
               <effectiveTime value="20100305"/>
               <component>
                  <section>
                     <id root="806b3fde-7184-45bf-ab30-4d302313d800"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>METABOLIC</title>
                     <text>edema<br/>weight gain<br/>fluid retention<br/>flushing or 
sweating<br/>hyperglycemia<br/>glycosuria<br/>hyperkalemia</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="1bd2a483-293f-491e-9c43-ce8ba74335c2"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>INTEGUMENTARY</title>
                     <text>pruritus<br/>rash; urticaria<br/>petechiae or ecchymosis<br/>exfoliative 
dermatitis<br/>erythema nodosum<br/>loss of hair<br/>Stevens-Johnson 
Syndrome<br/>erythema multiforme<br/>toxic epidermal necrolysis</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ccc602f3-6bff-4d47-9f2c-bf262df9b792"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>HEMATOLOGIC</title>
                     <text>leukopenia<br/>bone marrow depression<br/>anemia secondary to obvious or occult 
gastrointestinal bleeding<br/>aplastic anemia<br/>hemolytic 
anemia<br/>agranulocytosis<br/>thrombocytopenic purpura<br/>disseminated 
intravascular coagulation</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f45e04cd-e8ab-4386-a80c-d5ff47078a0b"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>HYPERSENSITIVITY</title>
                     <text>acute anaphylaxis<br/>acute respiratory distress<br/>rapid fall in blood pressure 
resembling a shock-like 
state<br/>angioedema<br/>dyspnea<br/>asthma<br/>purpura<br/>angiitis<br/>pulmonary 
edema<br/>fever</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ddbaf58b-45ae-4077-8943-903a3a51901f"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>GENITOURINARY</title>
                     <text>hematuria<br/>vaginal bleeding<br/>proteinuria, nephrotic syndrome, interstitial 
nephritis<br/>BUN elevation<br/>renal insufficiency, including renal failure</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="6483b305-f31a-4f50-a31b-9ed820bd1ac3"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>MISCELLANEOUS</title>
                     <text>epistaxis<br/>breast changes, including enlargement and tenderness, or 
gynecomastia</text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2d4afbf3-03c0-462d-82fe-aeebef768f5b"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>CAUSAL RELATIONSHIP UNKNOWN</title>
                     <text>
                        <paragraph>Other reactions have been reported but occurred under 
circumstances where a causal relationship could not be established. However, in 
these rarely reported events, the possibility cannot be excluded. Therefore, 
these observations are being listed to serve as alerting information to 
physicians:</paragraph>
                        <paragraph>
                           <content>Cardiovascular:</content> thrombophlebitis</paragraph>
                        <paragraph>
                           <content>Hematologic:</content> Although there have been several 
reports of leukemia, the supporting information is weak.</paragraph>
                        <paragraph>
                           <content>Genitourinary:</content> urinary frequency</paragraph>
                        <paragraph>A rare occurrence of fulminant necrotizing fasciitis, particularly in 
association with Group A β-hemolytic streptococcus, has been described in 
persons treated with non-steroidal anti-inflammatory agents, including 
indomethacin, sometimes with fatal outcome <content styleCode="bold">(see also PRECAUTIONS: 
General).</content>
                        </paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="d945649f-07b1-4e03-8337-3453cd6dde72"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>The following symptoms may be observed following overdosage: 
nausea, vomiting, intense headache, dizziness, mental confusion, disorientation, 
or lethargy. There have been reports of paresthesias, numbness and 
convulsions.</paragraph>
                  <paragraph>Treatment is symptomatic and supportive. The stomach should be emptied as 
quickly as possible if the ingestion is recent. If vomiting has not occurred 
spontaneously, the patient should be induced to vomit with syrup of ipecac. If 
the patient is unable to vomit, gastric lavage should be performed. Once the 
stomach has been emptied, 25 g or 50 g of activated charcoal may be given. 
Depending on the condition of the patient, close medical observation and nursing 
care may be required. The patient should be followed for several days because 
gastrointestinal ulceration and hemorrhage have been reported as adverse 
reactions of indomethacin. Use of antacids may be helpful.</paragraph>
                  <paragraph>The oral LD<sub>50</sub> of indomethacin in mice and rats (based 
on 14 day mortality response) was 50 and 12 mg/kg, respectively</paragraph>
               </text>
               <effectiveTime value="20100305"/>
            </section>
         </component>
         <component>
            <section>
               <id root="f50bbffb-5d00-4d14-8594-b160d6f45df3"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Carefully consider the potential benefits and risks of 
indomethacin and other treatment options before deciding to use indomethacin. 
Use the lowest effective dose for the shortest duration consistent with 
individual patient treatment goals <content styleCode="bold">(see WARNINGS).</content>
                  </paragraph>
                  <paragraph>After observing the response to initial therapy with indomethacin, the dose 
and frequency should be adjusted to suit an individual patient's needs.</paragraph>
                  <paragraph>Indomethacin is available as 75 mg capsules.</paragraph>
                  <paragraph>Adverse reactions appear to correlate with the size of the dose of 
indomethacin in most patients but not all. Therefore, every effort should be 
made to determine the smallest effective dosage for the individual patient</paragraph>
               </text>
               <effectiveTime value="20100305"/>
               <component>
                  <section>
                     <id root="494aa56e-c63f-43eb-b999-3220470b38a3"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>Pediatric Use</title>
                     <text>Indomethacin ordinarily should not be prescribed for pediatric patients 14 years 
of age and under <content styleCode="bold">(see WARNINGS).</content>
                     </text>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4ddea55f-355e-4eed-8a4b-a9cc821e5245"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>Adult Use</title>
                     <text>
                        <paragraph>Dosage Recommendations for Active Stages of the Following:</paragraph>1. 
Moderate to severe rheumatoid arthritis including acute flares of chronic 
disease; moderate to severe ankylosing spondylitis; and moderate to severe 
osteoarthritis.<br/> <br/>Suggested Dosage: Indomethacin capsules 75 mg b.i.d. or 
t.i.d. If this is well tolerated, increase the daily dosage by 75 mg, if 
required by continuing symptoms, at weekly intervals until a satisfactory 
response is obtained or until a total daily dose of 150 mg to 200 mg is reached. 
DOSES ABOVE THIS AMOUNT GENERALLY DO NOT INCREASE THE EFFECTIVENESS OF THE DRUG. 
<paragraph>In patients who have persistent night pain and/or morning stiffness, the 
giving of a large portion, up to a maximum of 100 mg, of the total daily dose at 
bedtime may be helpful in affording relief. The total daily dose should not 
exceed 200 mg. In acute flares of chronic rheumatoid arthritis, it may be 
necessary to increase the dosage by 75 mg daily.</paragraph>
                        <paragraph>If minor adverse effects develop as the dosage is increased, reduce the 
dosage rapidly to a tolerated dose and OBSERVE THE PATIENT CLOSELY.</paragraph>
                        <paragraph>If severe adverse reactions occur, STOP THE DRUG. After the acute phase of 
the disease is under control, an attempt to reduce the daily dose should be made 
repeatedly until the patient is receiving the smallest effective dose or the 
drug is discontinued.</paragraph>
                        <paragraph>Careful instructions to, and observations of, the individual patient are 
essential to the prevention of serious, irreversible, including fatal, adverse 
reactions.</paragraph>
                        <paragraph>As advancing years appear to increase the possibility of adverse reactions, 
indomethacin should be used with greater care in the elderly <content styleCode="bold">(see PRECAUTIONS: 
Geriatric Use).</content>
                        </paragraph>2. 
Acute painful shoulder (bursitis and/or tendinitis).<br/> <br/>Initial Dose: 
75 mg to 150 mg daily in 3 or 4 divided doses. The drug should be discontinued 
after the signs and symptoms of inflammation have been controlled for several 
days. The usual course of therapy is 7 to 14 days.<br/>  
3. 
Acute gouty arthritis.<br/> <br/>Suggested Dosage: Indomethacin capsules 75 mg 
t.i.d. until pain is tolerable. The dose should then be rapidly reduced to 
complete cessation of the drug. Definite relief of pain has been reported within 
2 to 4 hours. Tenderness and heat usually subside in 24 to 36 hours, and 
swelling gradually disappears in 3 to 5 days</text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="d56acefb-5a65-414e-ba01-2cbf0c31cbd6"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</title>
               <text>Please ask your Pharmacist for a complete medication guide for this prescription.<br/>
               </text>
               <effectiveTime value="20100305"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2a3da450-8471-44bf-99b2-5a55d180fe97"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Manufactured by KVK-Tech Inc.Indomethacin Extended-release Capsules USP 75 mg are supplied as yellow opaque cap,<br/>natural body with black imprint K-16 on both cap and body, filled with white pellets.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold"> Available as follows:</content>
                     </content>
                  </paragraph>
                  <paragraph>NDC 12634-160-91 Blister Pack UD 1's<br/>NDC 12634-160-54 Blister Pack Card of 14<br/>NDC 12634-160-55 Blister Pack Card of 15<br/>NDC 12634-160-57 Blister Pack Card of 20<br/>NDC 12634-160-25 Blister Pack Card of 25<br/>NDC 12634-160-59 Blister Pack Card of 30<br/>NDC 12634-160-97 Bottle of 7<br/>NDC 12634-160-00 Bottle of 10<br/>NDC 12634-160-84 Bottle of 14<br/>NDC 12634-160-85 Bottle of 15<br/>NDC 12634-160-80 Bottle of 20<br/>NDC 12634-160-79 Bottle of 25<br/>NDC 12634-160-71 Bottle of 30<br/>NDC 12634-160-60 Bottle of 60</paragraph>Manufactured by Epic Pharm LLC for Sandoz INC. Indomethacin extended-release capsules 75 mg is supplied as green and clear 
capsules, imprinted <content styleCode="italics">E </content>720.<br/>
                  <br/>
                  <content styleCode="bold">Available as follows:</content>
                  <br/>
                  <br/>NDC 12634-838-91 Blister Pack UD 1's<br/>NDC 12634-838-66 Blister Pack Card of 6<br/>NDC 12634-838-67 Blister Pack Card of 7<br/>NDC 12634-838-61 Blister Pack Card of 10<br/>NDC 12634-838-54 Blister Pack Card of 14<br/>NDC 12634-838-55 Blister Pack Card of 15<br/>NDC 12634-838-57 Blister Pack Card of 20<br/>NDC 12634-838-59 Blister Pack Card of 30<br/>NDC 12634-838-95 Bottle of 5<br/>NDC 12634-838-97 Bottle of 7<br/>NDC 12634-838-00 Bottle of 10<br/>NDC 12634-838-84 Bottle of 14<br/>NDC 12634-838-85 Bottle of 15<br/>NDC 12634-838-80 Bottle of 20<br/>NDC 12634-838-79 Bottle of 25<br/>NDC 12634-838-71 Bottle of 30<br/>NDC 12634-838-50 Bottle of 50<br/>NDC 12634-838-60 Bottle of 60<br/>NDC 12634-838-90 Bottle of 90<br/>
                  <br/>
                  <br/>
                  <br/>
                  <linkHtml href="#section-"/>
               </text>
               <effectiveTime value="20100305"/>
            </section>
         </component>
         <component>
            <section>
               <id root="3a49f40a-af54-433b-b7ef-fe231f42caf3"/>
               <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
               <title>STORAGE AND DISPENSING</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Store at 20° to 25°C (68° to 77°F). [See USP for 
Controlled Room Temperature.]<br/>Protect from light.</content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP using a 
child-resistant closure.<br/>
                     <content styleCode="bold">PHARMACIST:</content> Dispense a Medication Guide with each 
prescription</paragraph>
               </text>
               <effectiveTime value="20100305"/>
            </section>
         </component>
         <component>
            <section>
               <id root="3f8c3401-bbd5-4879-ae96-b6e90a0cf131"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL AND PRINCIPAL DISPLAY PANEL
ADDITIONAL LABELS UPON REQUEST</title>
               <text>
                  <content styleCode="bold">NDC 12634-160-71 30 CAPSULES</content>
                  <br/>Each Capsule Contains:<br/>
                  <content styleCode="bold">Indomethacin E-R 75MG</content>
                  <br/>
                  <content styleCode="bold">RX Only</content>
                  <br/>Usual Adult Dosage:<br/>See insert for full prescribing information. Dispense<br/>with a Patient Medication Guide.<br/>
                  <content styleCode="underline">Keep this and all Medication out of the reach of Children</content>.<br/>
                  <content styleCode="bold">Manufactures by:</content>
                  <br/>Epic Pharma LLC<br/>For Sandoz, Inc.<br/>NDC 0185-0720-60<br/>
                  <content styleCode="bold">Repackaged and Distributed by</content>:<br/>Apotheca, Inc.<br/>Phoenix, AZ. 85006<br/>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM2"/>
                  <br/>
                  <br/>
                  <br/>
                  <br/>
                  <br/>
                  <br/>
                  <br/>
                  <br/>
                  <br/>
                  <br/>
                  <br/>
               </text>
               <effectiveTime value="20100305"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM2">
                     <text>image of label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="indo-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>